ps://www.youtube.com/watch?v=Rlfs6hthwGo", "range": {"length":18,"start":172}, "type": "lin
k"}],"identifier":" anf-body-
49","“inlineTextStyles":[{"range": {"length":234,"start":0},"textsStyle":" anf-ts-
i"}, {"range™: {"length":234,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body","text":"Since Labor Day, Mr. Menendezad€™s campaign, perhaps ina
sign of vulnerability, has aggressively ramped up its advertising campaign, with a majority of the political attacks accusing Mr. Hugin of raising drug prices to maximize profits.","type":"text"}, {"identifier":" anf-body- 50", "inlineTextStyles": [{"range": {"length":332,"start":0},"textsStyle":" anf-ts-
i"}, {"range™: {"length":332,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default— body", "role":"body", "text":"In 2017, after Mr. Hugin had stepped down as chief executive and becom xecutive chairman, the company suffered two major setbacks in its development pipeline: A drug it had hoped would be a breakthrough in treating Crohnda€™s disease failed to outperform a control group and Otezla, a psoriasis drug, badly missed sales expectations.","type"™:"text"}, {"additions"™: [{"URL":"https://ir.celgene.com/press-— releases/press-release-details/2017/Celgene-Provides-Update-on-GED-0301-mongersen Inflammatory-Bowel-Diseas Program/default.aspx", "range": {"length":39, "start":21}, "type"™:"link"}, {"URL":"https://i r.celgene.com/press-releases/press-release-details/2017/Celgene-Provides-Update-on-GED 0301-mongersen-Inflammatory-Bowel-Diseas Program/default.aspx", "range": {"length":20,"start":60}, "type"™:"link"}, {"URL":"https://w ww.streetinsider.com/Analystt+Comments/Celgene+%28CELG%$29%3A+Pricet+tIncreases+Add+8ctiInti T+- +Suntrust/13411298 html", "range": {"length":64, "start ":161}, "type"™:"link"}], "identifier"
W
7" anf-body- 51", "inlineTextStyles": [{"range": {"length":364,"start":0},"textsStyle":" anf-ts- i"}, {"range™: {"length":364,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-
body", "role":"body", "text":"On the same day that Celgene announced it was scrapping the Crohna這s disease drug, it increased the price of Revlimid from $17,014 a bottle to $18,546, according to a report by Yatin Suneja, an analyst who follows the industry. It was the third price increase of Revlimid in 2017, representing a nearly 20 percent price increase for the drug from the previous year.", "type™:"text"}, {"additions"™: [{"URL":"https://d18rn0p25nwréd.cloudfront.net/CIK- 0000816284/ddd3eeae-cal0e-48c5-8132
54186f548874. pdf", "range": {"length":20,"start":0},"type"™:"link"}],"identifier":" anf- body-52", "inlineTextStyles": [{"range"™:{"length":156,"start":0},"textStyle":" anf-ts- i"},{"range"™:{"length":156,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-
body", "role": "body", "text"™:"In financial filings, Celgene said these price hikes were a main reason the drugaé&€™s net sales increased in 2017 by about $1.2 billion over the
previous year.","type":"text"}, {"identifier":" anf-body- 53","inlineTextStyles":[{"range": {"length":314,"start":0},"textstyle":" anf-ts-
I"}, {"range™: {"length":314,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role":"body", "text":"Ronny Gal, a securities analyst at Sanford C. Bernstein &
Company who follows the pharmaceutical industry, said drug companies have generally been dA€cetone deafa€ when it comes to raising the price of their monopoly products. a€eCelgene clearly has been there, but has not been any worse than the main players, a4€
he said.", "type": "text"}, {"identifier":" anf-body- 54","inlineTextStyles": [{"range": {"length":412,"start":0},"textsStyle":" anf-ts- i"}, {"range"™: {"length":412,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default— body", "role":"body", "text":"The tactics can carry a human cost. Last year, Elaine
Kodish, a 76-year-old retir from Los Angeles, briefly stopped taking Revlimid after her Medicare drug plan required she pay more than $450 a month for the drug that keeps her multiple myeloma in check. Ms. Kodish said she bought stock in Celgene when sh started taking Revlimid in 2016, as a way of supporting a company she believed was
keeping her alive.","type":"text"}, {"identifier":" anf-body- 55","inlineTextStyles": [{"range": {"length":364, "start":0},"textsStyle":" anf-ts-
i"}, {"range™: {"length":364,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"But after a series of price increases hav xposed her to
ballooning out-of-pocket costs 4€" she has since returned to taking Revlimid, which now costs her about $785 per month 4€" she said she recently sold her stake. A€el4e™m grateful to the drug companies, dond€™t get me wrong,a€ Ms. Kodish said. d€ceHowever, they canaéd€™t be compensated on the backs of people who are dying.a€","type":"text"}, {"components": [{"identifier":" anf-heading6- i","layout":"related-coverage-heading", "role": "heading6", "text": "RELATED COVERAGE", "textStyle":"related-
coverage", "type": "text"}, {"additions"™: [{"URL":"https://www.nytimes.com/2017/07/25/healt h/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer
HOUSE_OVERSIGHT_028421